Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Hickman

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Immunity|April 6, 2021
Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responsesMaryam Mukhamedova, Daniel Wrapp, Chen-Hsiang Shen, et al.
JCI Insight|April 8, 2024
Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LSSeemal F Awan, Amarendra Pegu, Larisa Strom, et al.
The New England Journal of Medicine|August 3, 2022
Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent MalariaRichard L Wu, Azza H Idris, Nina M Berkowitz, et al.
The Lancet. HIV|May 23, 2025
Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adultsRichard L Wu, Katherine V Houser, Martin R Gaudinski, et al.
The Lancet. Infectious Diseases|August 6, 2023
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trialBetty Mwesigwa, Katherine V Houser, Amelia R Hofstetter, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Immunity|April 6, 2021
Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responsesMaryam Mukhamedova, Daniel Wrapp, Chen-Hsiang Shen, et al.
JCI Insight|April 8, 2024
Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LSSeemal F Awan, Amarendra Pegu, Larisa Strom, et al.
The New England Journal of Medicine|August 3, 2022
Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent MalariaRichard L Wu, Azza H Idris, Nina M Berkowitz, et al.
The Lancet. HIV|May 23, 2025
Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adultsRichard L Wu, Katherine V Houser, Martin R Gaudinski, et al.
The Lancet. Infectious Diseases|August 6, 2023
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trialBetty Mwesigwa, Katherine V Houser, Amelia R Hofstetter, et al.
Pageof 8